KR20250027279A - B형 간염 감염 치료를 위한 방법 및 조성물 - Google Patents

B형 간염 감염 치료를 위한 방법 및 조성물 Download PDF

Info

Publication number
KR20250027279A
KR20250027279A KR1020257005383A KR20257005383A KR20250027279A KR 20250027279 A KR20250027279 A KR 20250027279A KR 1020257005383 A KR1020257005383 A KR 1020257005383A KR 20257005383 A KR20257005383 A KR 20257005383A KR 20250027279 A KR20250027279 A KR 20250027279A
Authority
KR
South Korea
Prior art keywords
thr
ser
hbsag
leu
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257005383A
Other languages
English (en)
Korean (ko)
Inventor
르네 월쉬
스티븐 로카르니니
한스 네터
로날드 파쿼르
Original Assignee
멜버른 헬스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 멜버른 헬스 filed Critical 멜버른 헬스
Publication of KR20250027279A publication Critical patent/KR20250027279A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
KR1020257005383A 2018-05-10 2019-05-09 B형 간염 감염 치료를 위한 방법 및 조성물 Pending KR20250027279A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862669663P 2018-05-10 2018-05-10
US62/669,663 2018-05-10
KR1020207034973A KR20210010872A (ko) 2018-05-10 2019-05-09 B형 간염 감염 치료를 위한 방법 및 조성물
PCT/US2019/031483 WO2019217654A1 (en) 2018-05-10 2019-05-09 Methods and compositions for the treatment of hepatitis b infection

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207034973A Division KR20210010872A (ko) 2018-05-10 2019-05-09 B형 간염 감염 치료를 위한 방법 및 조성물

Publications (1)

Publication Number Publication Date
KR20250027279A true KR20250027279A (ko) 2025-02-25

Family

ID=68466904

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020257005383A Pending KR20250027279A (ko) 2018-05-10 2019-05-09 B형 간염 감염 치료를 위한 방법 및 조성물
KR1020207034973A Ceased KR20210010872A (ko) 2018-05-10 2019-05-09 B형 간염 감염 치료를 위한 방법 및 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207034973A Ceased KR20210010872A (ko) 2018-05-10 2019-05-09 B형 간염 감염 치료를 위한 방법 및 조성물

Country Status (10)

Country Link
US (4) US11773141B2 (cg-RX-API-DMAC7.html)
EP (2) EP4389222A3 (cg-RX-API-DMAC7.html)
JP (2) JP2021522864A (cg-RX-API-DMAC7.html)
KR (2) KR20250027279A (cg-RX-API-DMAC7.html)
CN (3) CN112513063A (cg-RX-API-DMAC7.html)
AU (2) AU2019267680C1 (cg-RX-API-DMAC7.html)
CA (1) CA3099726A1 (cg-RX-API-DMAC7.html)
ES (1) ES2985391T3 (cg-RX-API-DMAC7.html)
PL (1) PL3810625T3 (cg-RX-API-DMAC7.html)
WO (1) WO2019217654A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025244940A1 (en) * 2024-05-21 2025-11-27 Clearb Therapeutics Ltd. Methods and compositions for mrna- and dna-based treatment of hepatitis b infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599231A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US6740323B1 (en) * 1999-11-24 2004-05-25 Chiron Corporation HBV/HCV virus-like particle
AUPQ912000A0 (en) * 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
CN100381463C (zh) * 2002-09-18 2008-04-16 中国人民解放军免疫学研究所 用于生产治疗用乙型肝炎疫苗或药物的免疫原及其制备方法和用途
EP1638993A4 (en) * 2003-06-10 2007-05-09 Univ Melbourne IMMUNOMODULATING COMPOSITIONS, APPLICATIONS THEREOF AND METHOD FOR THE PRODUCTION THEREOF
AU2015259470A1 (en) * 2014-05-16 2016-11-10 Yale University Virus like vesicles (VLVs) based vaccines to prevent or treat chronic hepatitis B virus (HBV) infection
WO2017059878A1 (en) * 2015-10-07 2017-04-13 Humabs Biomed Sa Antibodies that potently neutralize hepatitis b virus and uses thereof

Also Published As

Publication number Publication date
AU2024227453A1 (en) 2024-11-21
CN112513063A (zh) 2021-03-16
JP2024105291A (ja) 2024-08-06
US12202862B2 (en) 2025-01-21
AU2019267680A1 (en) 2020-11-26
KR20210010872A (ko) 2021-01-28
US20250145669A1 (en) 2025-05-08
US11773141B2 (en) 2023-10-03
JP2021522864A (ja) 2021-09-02
EP3810625B1 (en) 2024-05-22
EP4389222A2 (en) 2024-06-26
AU2019267680C1 (en) 2025-02-27
EP4389222A3 (en) 2024-08-28
WO2019217654A1 (en) 2019-11-14
EP3810625A1 (en) 2021-04-28
CN119113097A (zh) 2024-12-13
ES2985391T3 (es) 2024-11-05
EP3810625A4 (en) 2022-05-11
US20220002349A1 (en) 2022-01-06
AU2019267680B2 (en) 2024-07-25
US20240150412A1 (en) 2024-05-09
CA3099726A1 (en) 2019-11-14
CN120571006A (zh) 2025-09-02
US20250333450A1 (en) 2025-10-30
PL3810625T3 (pl) 2025-03-03

Similar Documents

Publication Publication Date Title
Pondé Expression and detection of anti-HBs antibodies after hepatitis B virus infection or vaccination in the context of protective immunity: RAA Pondé
Sominskaya et al. Construction and immunological evaluation of multivalent hepatitis B virus (HBV) core virus-like particles carrying HBV and HCV epitopes
Zhang et al. A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice
US9683029B2 (en) Antibody composition for prevention or treatment of mutant hepatitis B virus infection
Hong et al. Characterization and application of precore/core‐related antigens in animal models of hepatitis B virus infection
Tang et al. A novel linear neutralizing epitope of hepatitis E virus
Chuai et al. Lentiviral backbone-based hepatitis B virus replicon-mediated transfer favours the establishment of persistent hepatitis B virus infection in mice after hydrodynamic injection
Wei et al. Neutralization effects of antibody elicited by chimeric HBV S antigen viral-like particles presenting HCV neutralization epitopes
Sun et al. Hepatitis B virus pre‐S region: Clinical implications and applications
US20250333450A1 (en) Methods and compositions for the treatment of hepatitis b infection
Su et al. Introducing adjuvant-loaded particulate hepatitis B core antigen as an alternative therapeutic hepatitis B vaccine component
HK40106023A (en) Methods and compositions for the treatment of hepatitis b infection
HK40040491A (en) Methods and compositions for the treatment of hepatitis b infection
HK40040491B (en) Methods and compositions for the treatment of hepatitis b infection
Sylvan et al. Anti-preS responses influence the anti-HBs response in newborns after vaccination with the third generation Sci-B-Vac™ vaccine
WO2025244940A1 (en) Methods and compositions for mrna- and dna-based treatment of hepatitis b infection
Cardell Studies on hepatitis B vaccination and factors associated with the vaccine response
Liu et al. N-linked glycosylation at an appropriate position in the Pre-S2 domain is critical for cellular and humoral immunity against middle HBV surface antigen
CN104474548B (zh) 预防和/或治疗慢性病毒感染的产品及方法
Shamseldin Development of Research Tools for Studying Hepatitis B Virus
Thompson et al. Hepatitis B virus
Basuni Aspects of HBV S gene variation
Onu Efficient cellular and humoral immune response and production of virus-neutralizing antibodies by the Hepatitis B Virus S/preS116-42 antigen
PL230663B1 (pl) Szczepionka, sposob jej otrzymywania, wyizolowane chimeryczne bialko, wektor ekspresyjny, zestaw zawierajacy szczepionke oraz kompozycja do zastosowania w profilaktyce zakazen powodowanych przez HCV i/lub HBV
Sloan Studies into the transmission of hepatitis B virus that mutate following therapy with nucleoside analogues and the potential for such transmission to be serologically undetectable

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250219

Application number text: 1020207034973

Filing date: 20201204

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250320

Comment text: Request for Examination of Application